Literature DB >> 12460890

HEPSIN inhibits cell growth/invasion in prostate cancer cells.

Vasantha Srikantan1, Michael Valladares, Johng S Rhim, Judd W Moul, Shiv Srivastava.   

Abstract

Expression of HEPSIN, a type II transmembrane serine protease in prostate cancer (CaP), has been highlighted by several studies analyzing CaP-specific gene expression alterations by cDNA microarray. Evaluations of the biological functions of HEPSIN in CaP cells are warranted for better assessment of its utility as a biomarker and/or therapeutic target. In stable clones of PC-3/HEPSIN transfectants, there was a dramatic reduction in the cell growth, cell invasion, and soft agar colony formation. A higher proportion of PC-3/HEPSIN cells were in the G(2)-M phase of the cell cycle, and there was also an increase in the cell population undergoing apoptosis. Preliminary analysis of HEPSIN transfections into LNCaP and DU145 cells further revealed cell growth-inhibitory effects. These results underscore that exogenous HEPSIN expression negatively regulates cell growth in metastatic CaP cell lines. Although the cause of the biological consequence of HEPSIN overexpression in primary CaP remains to be determined, the negative cell growth-regulatory effects of HEPSIN in metastatic CaP cells reported here have unraveled possible cellular and molecular mechanisms underlying observations that link decreased/loss of HEPSIN expression with poor prognosis of CaP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460890

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.

Authors:  Stephanie M Wittig-Blaich; Lukasz A Kacprzyk; Thorsten Eismann; Melanie Bewerunge-Hudler; Petra Kruse; Eva Winkler; Wolfgang S L Strauss; Raimund Hibst; Rudolf Steiner; Mark Schrader; Daniel Mertens; Holger Sültmann; Rainer Wittig
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

2.  Detection of early prostate cancer using a hepsin-targeted imaging agent.

Authors:  Kimberly A Kelly; Sunita R Setlur; Robert Ross; Rajesh Anbazhagan; Peter Waterman; Mark A Rubin; Ralph Weissleder
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

3.  Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.

Authors:  Sylvia Herter; Derek E Piper; Wade Aaron; Timothy Gabriele; Gene Cutler; Ping Cao; Ami S Bhatt; Youngchool Choe; Charles S Craik; Nigel Walker; David Meininger; Timothy Hoey; Richard J Austin
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

4.  Identification and characterization of small-molecule inhibitors of hepsin.

Authors:  John R Chevillet; Gemma J Park; Antonio Bedalov; Julian A Simon; Valeri I Vasioukhin
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

Review 5.  Molecular imaging of prostate cancer: a concise synopsis.

Authors:  Hossein Jadvar
Journal:  Mol Imaging       Date:  2009 Mar-Apr       Impact factor: 4.488

6.  PDCD10 interacts with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway.

Authors:  Xi Ma; Hongshan Zhao; Jingxuan Shan; Feng Long; Yaoyao Chen; Yingyu Chen; Yingmei Zhang; Xiao Han; Dalong Ma
Journal:  Mol Biol Cell       Date:  2007-03-14       Impact factor: 4.138

7.  Hepsin activates prostasin and cleaves the extracellular domain of the epidermal growth factor receptor.

Authors:  Mengqian Chen; Li-Mei Chen; Chen-Yong Lin; Karl X Chai
Journal:  Mol Cell Biochem       Date:  2010-04       Impact factor: 3.396

8.  Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.

Authors:  Jiangyong Miao; David Mu; Burce Ergel; Rajasekhar Singavarapu; Zhenfeng Duan; Scott Powers; Esther Oliva; Sandra Orsulic
Journal:  Int J Cancer       Date:  2008-11-01       Impact factor: 7.396

Review 9.  Type II transmembrane serine proteases as potential targets for cancer therapy.

Authors:  Andrew S Murray; Fausto A Varela; Karin List
Journal:  Biol Chem       Date:  2016-09-01       Impact factor: 3.915

10.  Fucoidan from seaweed Fucus vesiculosus inhibits migration and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways.

Authors:  Hyunkyoung Lee; Jong-Shu Kim; Euikyung Kim
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.